7ª Edição

Research presented at ASCO 2020 might impact conduct on locally advanced rectal cancer

per: Grupo Oncoclínicas
Research presented at ASCO 2020 might impact conduct on locally advanced rectal cancer

Scientific commission

Alexandre Jácome
Alexandre Jácome
Alexandre Palladino
Alexandre Palladino
Gabriel Prolla
Gabriel Prolla
Roberto Gil
Roberto Gil

Contributors

Diego Chaves Rezende Morais
Diego Chaves Rezende Morais
Flora Moraes Lino da Silva
Flora Moraes Lino da Silva

Treatment standards for patients with locally advanced rectal cancer might be updated. The reason lies in the results of RAPIDO research, published at the ASCO 2020 congress.

Local control on this kind of cancer improved over the past few years. However, systemic relapses remain high, even with adjuvant chemotherapy. This occurs, possibly, due to low adherence to this conduct. In this context, the phase III randomized research (n=920) tested, on its experimental branch, a hypofractionated (short-term) radiotherapy regimen followed by chemotherapy before total mesorectal excision (TME). According to Oncoclinicas Group Botafogo (Rio de Janeiro) clinical oncology doctor Flora Moraes Lino da Silva, results showed improvement not only in complete pathologic response rate comparisons, but also illness-free survival rates, which reinforces recommendation of not just short term radiotherapy but also total neoadjuvant therapy as an option for these patients. “With such robust data, this protocol is soon expected to become standard, specially for very advanced rectal tumors”, concludes Diego Chaves Rezende Morais, radio-oncologist doctor at Recife Radiotherapy, an Oncoclinicas Group clinic in Pernambuco.

For the full article, download.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L